BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience

BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience

BackgroundPediatric low-grade gliomas (pLGGs) have an overall survival of over 90%; however, patients harboring a BRAFV600E alteration may have worse outcomes, particularly when treated with classic chemotherapy. Combined BRAF/MEK inhibition following incomplete resection demonstrated improved outco...

Full description

Saved in:
Bibliographic Details
Main Authors: S. S. McThenia, K. M. Reddy, E. Damaraju, E. Castellino, Z. He, R. Beer, F. Chien, R. C. Castellino, A. E. Goldman-Yassen, J. R. Fangusaro, T. MacDonald
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
BRAFV600E-mutation
pLGG
BRAF inhibitor
monotherapy
dabrafenib
CNS tumors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1505951/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items